Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, describes the current indications for PARP inhibitors in ovarian cancer.
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, describes the current indications for PARP inhibitors in ovarian cancer.
Transcript
Can you discuss the current approved indications for PARP inhibitors in ovarian cancer?
Poly (ADP-ribose) polymerase, or PARP, inhibitors are oral anti-cancer therapies. They're approved in 4 tumor types—breast, there are 2 of them; pancreatic; and then in prostate, there are also 2 of them. And in those breast, pancreatic and prostate, there are molecularly defined populations. I'd like to talk to you about the ovarian cancer indications.
We have 9 PARP inhibitor indications in ovarian cancer. I can kind of put them into groups. The first PARP approved in treatment, that first group, was called olaparib in December of 2014. So we've been sort of using PARP inhibitors in the clinic for 6 years. And olaparib was an accelerated approval, as were the others: rucaparib, and also niraparib. And again, in the treatment setting of later lines of therapy. They're all molecularly defined populations. Olaparib is germline BRCA mutation, rucaparib is germline and somatic mutation, and niraparib is BRCA mutation or homologous recombination repair-deficient, platinum-sensitive cancer; so patients that have a platinum-sensitive relapse that have the molecular signature, which we abbreviate HRD.
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Most Patients With Mucinous Ovarian Cancer Don't Need Perioperative GI Endoscopy
April 12th 2024A new study suggests routine gastrointestinal (GI) endoscopy is not needed for most patients with mucinous ovarian cancer in the perioperative setting due to a lack of statistically significant overall survival benefits.
Read More
Model Including Diffusion-Weighted MRI More Accurately Predicts Ovarian Cancer Resectability
April 4th 2024A recent study suggests a modified model incorporating diffusion-weighted MRI can more accurately predict ovarian cancer primary debulking surgery outcomes compared with the standard, widely used Memorial Sloan Kettering Cancer Center risk model.
Read More